A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PARALLEL GROUPS DETERMINING THE DOSE RANGE OF L-000883191 IN COPD PATIENTS

Not Applicable

• Conditions: -J44 Other chronic obstructive pulmonary disease; Other chronic obstructive pulmonary disease; J44

• Registration Number: PER-029-04
• Lead Sponsor: MERCK SHARP & DOHME PERU S.R.L.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-06-25
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

to. The patient has successfully completed the schedule until Visit 20 of Protocol 005-21, inclusive.
b. The patient understands the study procedures and agrees to participate in the study by providing written informed consent.

Exclusion Criteria

a. In the 2 consecutive weeks immediately prior to the first visit of
In this extension, the patient had some serious clinical or laboratory adverse event, related to the drug, during his participation in Protocol 005-21, which, according to the medical criteria of the investigators, would exclude the patient from participating or concluding the study. .
b. The patient has significant changes in his general medical condition since his enrollment in Protocol 005-21, which, according to the medical criteria of the investigators, would exclude the patient from participating or concluding the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified